Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 8/20 | 1.00 |
| ▸ | ESR2 | Q92731 | 8/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | MT-CO2 | P00403 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 3/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | LMNA | P02545 | 3/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.37 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.37 |
| ▸ | DHFR | P00374 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15290442 | 0.95 | ESR1 (0.91) | ESR1ESR2HSD17B10KDM4EALDH1A1 | |
| SCHEMBL15490712 | 0.93 | ESR1 (0.86) | ESR1ESR2HSD17B10KDM4EALDH1A1 | |
| SCHEMBL9067488 | 0.86 | ESR1 (0.76) | ESR1ESR2HSD17B10KDM4EALDH1A1 | |
| SCHEMBL14822008 | 0.84 | ESR1 (0.72) | ESR1ESR2HSD17B10KDM4EALDH1A1 | |
| SCHEMBL2406793 | 0.84 | ESR1 (1.00) | ESR1ESR2KDM4ELMNANPC1 | |
| SCHEMBL16589776 | 0.80 | ESR1 (0.67) | ESR1ESR2HSD17B10KDM4EALDH1A1 | |
| SCHEMBL1810392 | 0.74 | ESR1 (0.59) | ESR1ESR2HSD17B10KDM4EALDH1A1 | |
| SCHEMBL15290443 | 0.74 | ESR1 (0.58) | ESR1ESR2HSD17B10KDM4EALDH1A1 | |
| SCHEMBL9361049 | 0.74 | ESR1 (0.58) | ESR1ESR2HSD17B10KDM4EALDH1A1 | |
| SCHEMBL2113799 | 0.73 | ESR1 (0.58) | ESR1ESR2ALDH1A1HPGDMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008130571-A1 | NUCLEAR RECEPTOR BINDING AGENTS | GTX, INC. (US) | 2008-10-30 | — | — | WO | claimed |
| US-20070265296-A1 | Nuclear receptor binding agents | GTX, INC. | 2007-11-15 | — | — | US | claimed |
| US-9624161-B2 | Estrogen receptor ligands and methods of use thereof | GTX, INC. (US) | 2017-04-18 | — | — | US | disclosed |
| US-9624161-B2 | Estrogen receptor ligands and methods of use thereof | GTX, INC. (US) | 2017-04-18 | — | — | US | disclosed |
| US-9427418-B2 | Estrogen receptor ligands and methods of use thereof | GTX, INC. (US) | 2016-08-30 | — | — | US | disclosed |
| US-9427418-B2 | Estrogen receptor ligands and methods of use thereof | GTX, INC. (US) | 2016-08-30 | — | — | US | disclosed |
| US-9409856-B2 | Estrogen receptor ligands and methods of use thereof | GTX, INC. (US) | 2016-08-09 | — | — | US | disclosed |
| US-9409856-B2 | Estrogen receptor ligands and methods of use thereof | GTX, INC. (US) | 2016-08-09 | — | — | US | disclosed |
| US-9409856-B2 | Estrogen receptor ligands and methods of use thereof | GTX, INC. (US) | 2016-08-09 | — | — | US | disclosed |
| US-20160031797-A1 | ESTROGEN RECEPTOR LIGANDS AND METHODS OF USE THEREOF | GTX, INC. | 2016-02-04 | — | — | US | disclosed |
| US-20160031797-A1 | ESTROGEN RECEPTOR LIGANDS AND METHODS OF USE THEREOF | GTX, INC. | 2016-02-04 | — | — | US | disclosed |
| US-20120077845-A1 | ESTROGEN RECEPTOR LIGANDS AND METHODS OF USE THEREOF | GTX, INC. | 2012-03-29 | — | — | US | disclosed |
| US-20120077845-A1 | ESTROGEN RECEPTOR LIGANDS AND METHODS OF USE THEREOF | GTX, INC. | 2012-03-29 | — | — | US | disclosed |
| WO-2011106317-A1 | ESTROGEN RECEPTOR LIGANDS AND METHODS OF USE THEREOF | GTX, INC. (US) | 2011-09-01 | — | — | WO | disclosed |
| US-20100267773-A1 | ESTROGEN RECEPTOR LIGANDS AND METHODS OF USE THEREOF | GTX, INC. | 2010-10-21 | — | — | US | disclosed |
| US-20100267773-A1 | ESTROGEN RECEPTOR LIGANDS AND METHODS OF USE THEREOF | GTX, INC. | 2010-10-21 | — | — | US | disclosed |
| WO-2010096801-A1 | ESTROGEN RECEPTOR LIGANDS AND METHODS OF USE THEREOF | GTX, INC. (US) | 2010-08-26 | — | — | WO | disclosed |
| US-20090062341-A1 | Nuclear receptor binding agents | GTX, INC | 2009-03-05 | — | — | US | disclosed |
| WO-2008130571-A1 | NUCLEAR RECEPTOR BINDING AGENTS | GTX, INC. (US) | 2008-10-30 | — | — | WO | disclosed |
| US-20070265296-A1 | Nuclear receptor binding agents | GTX, INC. | 2007-11-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120077845-A1 | ESTROGEN RECEPTOR LIGANDS AND METHODS OF USE THEREOF | GNRHR, LHCGR, SHBG | ESR1 21/4885ESR2 15/4885HSD17B10 232/4885 |
| US-20160031797-A1 | ESTROGEN RECEPTOR LIGANDS AND METHODS OF USE THEREOF | ESRRB, ESRRA, ESR2 | ESR1 7/4885ESR2 3/4885HSD17B10 331/4885 |
| US-20070265296-A1 | Nuclear receptor binding agents | GPER1, ESRRG, ESR2 | ESR1 5/4885ESR2 3/4885HSD17B10 639/4885 |
| US-20090062341-A1 | Nuclear receptor binding agents | GPER1, ESRRG, ESR2 | ESR1 5/4885ESR2 3/4885HSD17B10 639/4885 |
| US-20100267773-A1 | ESTROGEN RECEPTOR LIGANDS AND METHODS OF USE THEREOF | SHBG, GNRHR, FSHR | ESR1 10/4885ESR2 9/4885HSD17B10 421/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.